QRP Research SEMAX 10mg
 
 
Semax is a synthetic heptapeptide derived from a short fragment of adrenocorticotropic hormone (ACTH) and has been investigated extensively in experimental neuroscience, molecular neurobiology and neurotrophic signalling research.
Semax consists of the seven-amino-acid sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). Structurally, it combines the ACTH(4–7) sequence Met-Glu-His-Phe with a C-terminal Pro-Gly-Pro (PGP) tripeptide.
Unlike full-length ACTH, Semax has primarily attracted research interest for its neurobiological and regulatory signalling properties rather than classical endocrine ACTH activity.
Experimental studies have investigated Semax in relation to neurotrophin expression, neuronal signalling, gene regulation and cellular responses to neurological stress.
Particular scientific interest has focused on brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). Experimental models have demonstrated changes in the expression of these neurotrophins and their associated receptors following exposure to Semax.
Semax has also been investigated in experimental models examining neurotransmitter-related pathways, inflammatory signalling, neuronal survival mechanisms and cellular responses to cerebral stress.
QRP Research SEMAX 10mg is supplied as a lyophilised research peptide intended exclusively for controlled laboratory, analytical and scientific investigation.
Key Research Areas
Semax has been investigated experimentally in relation to:
BDNF and neurotrophic signalling
NGF-related pathways
Trk receptor signalling
Neuronal gene expression
Neurotransmitter-associated mechanisms
Neuronal plasticity research
Cellular stress-response pathways
Neuroinflammatory signalling
Neuronal survival mechanisms
ACTH-derived peptide biology
Pro-Gly-Pro (PGP) peptide signalling
Peptide metabolism and biodegradation
Central nervous system research
A particularly interesting characteristic of Semax is its relationship to ACTH(4–7) combined with the C-terminal Pro-Gly-Pro sequence, creating a peptide with research characteristics distinct from full-length ACTH.
Its reported interactions with BDNF, NGF and associated neurotrophic signalling pathways have made Semax a useful experimental compound for investigating molecular mechanisms involved in neuronal signalling and cellular adaptation.
Research findings involving Semax should not be interpreted as evidence of established cognitive-enhancing, neuroprotective, therapeutic or other clinical effects of this research product.
Product Specification
Compound: Semax
Research Name: ACTH(4–7)-Pro-Gly-Pro
Compound Type: Synthetic heptapeptide / ACTH-derived peptide
Amino Acid Sequence: Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP)
Peptide Length: 7 amino acids
Related Sequence: ACTH(4–7) + Pro-Gly-Pro
Form: Lyophilised peptide
Quantity: 10mg per vial
Brand: QRP Research
Application: Laboratory and scientific research
Why QRP Research?
QRP Research supplies specialist research materials with an emphasis on quality, consistency and traceability. Products are securely packaged and clearly identified for their intended laboratory application.
Storage
Store in a cool, dry and dark environment, protected from excessive heat, direct light and moisture.
Appropriate laboratory storage procedures should be followed to preserve the stability and integrity of the research material.
Research Use Notice
FOR RESEARCH USE ONLY.
This product is supplied exclusively for laboratory, analytical and scientific research.
NOT for human consumption or administration.
NOT for animal consumption or administration.
NOT a medicine, food supplement or cosmetic product.
NOT intended to diagnose, treat, cure or prevent any disease.
No human dosing or administration instructions are provided.
Intended to be handled only by appropriately qualified researchers or laboratory professionals.
QRP Research SEMAX 10mg is supplied strictly as a research material for non-clinical laboratory investigation.